$18.24
+0.94%Mirion Technologies, Inc. provides radiation detection, measurement, analysis, and monitoring products and services in the United States, Canada, the United Kingdom, France, Germany, Finland, China, Belgium, Netherlands, Estonia, and Japan. It operates through two segments, Medical and Industrial. The medical segment offers radiation oncology quality assurance and dosimetry solutions; patient safety solutions for diagnostic imaging and radiation therapy centers; radiation therapy quality assurance solutions for calibrating and verifying imaging and treatment accuracy; and radionuclide therapy products for nuclear medicine applications, such as shielding, product handling, medical imaging furniture, and rehabilitation products. This segment supports applications in medical diagnostics, cancer treatment, practitioner safety, and rehabilitation. The Industrial segment focuses on addressing critical radiation safety, measurement, and analysis applications; and provides personal radiation detection, identification equipment, and analysis tools. The company's products and solutions also include nuclear medicines, dosimeters, contamination and clearance monitors, reactor instrumentation and control equipment and systems, medical and industrial imaging systems and related accessories, alpha spectroscopy instruments, alpha/beta counting instruments, and gamma spectroscopy detector systems; and electrical penetration, cancer diagnostics, software, and other services. It serves hospitals, clinics and urgent care facilities, dental and veterinary offices, radiation treatment facilities, OEMs for radiation therapy, laboratories, military organizations, government agencies, industrial companies, power and utility companies, reactor design firms, and NPPs. The company was formerly known as Global Monitoring Systems, Inc. and changed its name to Mirion Technologies, Inc. in January 2006. Mirion Technologies, Inc. was incorporated in 2005 and is headquartered in Atlanta, Georgia.
CMO & Senior Vice President of Government Affairs
Chief Accounting Officer
Chief Digital Officer
Chief Financial Officer
Compensation
$1,172,476
Chief Human Resources Officer
Compensation
$524,506
Chief Legal Officer, Chief Compliance Officer & Secretary
Compensation
$694,641
Chief Marketing Officer
Chief Revenue Officer
Chief Technology Officer
Founder, Medical Group President, Chief Executive Officer & Chairman
Compensation
$1,930,829
Group President of Technologies
Compensation
$719,537
Vice President of Investor Relations
During the last 12 months, insiders have sold $31.71M worth of MIR shares, with no buying activity reported.
0
0.00
8.4K
164.98K
-165K
-$165K
0
0.00
350.0K
8.65M
-8.7M
-$8.65M
0
0.00
407.5K
10.10M
-10.1M
-$10.10M
0
0.00
597.2K
12.79M
-12.8M
-$12.79M
No buying activity
Kingsley Lawrence D
Director
$15.80M
Logan Thomas D
Director, Officer: Chief Executive Officer
$10.74M
Schopfer Brian
Officer: Chief Financial Officer
$2.96M
Eloy Loic
Officer: Nuclear & Safety President
$1.70M
Lee Emmanuelle
Officer: Chief Legal Officer
$343K
Strong bearish signal with $31.71M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
MIR - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 01, 2026 | May 13, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 01, 2026 | May 13, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 01, 2025 | May 15, 2025 | 2025 | |
DEF 14A DEF 14A 2023 N/A | April 23, 2024 | December 31, 2023 | 2023 | |
DEF 14A DEF 14A N/A | April 24, 2023 | April 24, 2023 | ||
DEF 14A DEF 14A 2021 N/A | April 20, 2022 | December 31, 2021 | 2021 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.